|
2. ETIOLOGIE
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
4.1 DÉP., DIAG. & PRONO. - PROSTATE
|
|
|
|
4.16 DÉP., DIAG. & PRONO. - PANCRÉAS
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
|
|
4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
|
5.2 PHARMA
|
|
|
|
|
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial [Takeda]
|
|
|
|
|
|
The addition of ixazomib to lenalidomide and dexamethasone resulted in an improvement in median progression-free survival (PFS) of 13.5 months (35.3 months versus 21.8 months; hazard ratio [HR] 0.83; p=0.073); however, it did not meet the threshold for statistical significance.
|
|
|
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
6.1 OBSERVATION
|
|
|
|
|
6.9 CONTROVERSES
|
|
|